CME Group's third quarter delivered what the second quarter could not: a clear return to double-digit growth. Adjusted EPS of $3.02 rose 12.7% year over year on revenue of $1.737 billion, up 13.0%. That is a sharp reacceleration from roughly 1% growth on both lines in Q2. The earnings surprise was thin, however. Adjusted EPS beat the $2.98 consensus by 0.3% and cleared the $3.01 Earnings Whisper by just a penny, while revenue topped the $1.71 billion consensus by 1.6%. That is the central tension. The growth story is visibly back, but the beat itself was modest, and it landed on a stock that had already priced in a good deal of the recovery.

The top line was driven by activity rather than pricing. Average daily volume reached a third-quarter record of 29.4 million contracts, up 16%, with double-digit gains in all six asset classes and record non-U.S. ADV of 9 million. Clearing and transaction fees grew a more modest 12% to $1.38 billion because the average rate per contract slipped to $0.679 from $0.702 a year ago, flat with Q2's $0.678.

Market data was the cleanest line in the report:

- Revenue rose 20% to a record $243 million.

- That extended a 34-quarter growth streak.

- It came despite smaller audit-related catch-up payments than in Q2.

On a GAAP basis, diluted EPS rose to $2.89 from $2.49. The gap to the adjusted figure is mostly purchased-intangible amortization, so the two measures tell the same story.

The quality question shows up in costs and margins. Adjusted expenses rose about 9% to $531.8 million. Licensing and other fee agreements climbed to $104.2 million from $81.6 million, a cost that scales with equity-index volume. The adjusted operating margin was 69.4%, essentially flat with Q2's 69.5% but well below Q1's record 72.8%. The adjusted net income margin eased to 62.4% from 63.4%. Net interest income also fell roughly 8% sequentially as clearinghouse cash balances dipped to $147 billion from $150 billion. Revenue is growing again, but margins are not expanding with it.

The tone of the call improved noticeably. Management had spent much of the Q2 call defending against perpetual-futures competition; this time it emphasized new products and what they could add to growth:

- Single stock futures have traded roughly 350,000 contracts, with 25 retail brokers live and more clearing firms coming in Q4.

- 24/7 gold and silver trading is producing weekend volumes of 20% to 30% of ADV.

- CME Securities Clearing remains on track for a December 7 launch ahead of the SEC Treasury clearing mandate.

- Cross-margining savings with FICC reached $2.3 billion per day in September, up from roughly $1 billion to $1.5 billion earlier in the year.

- Overall margin savings for clients topped $100 billion per day.

- Retail client acquisition grew at a double-digit rate for a tenth straight quarter.

- Further out, escalators in the Cboe-S&P license extension should benefit the S&P DJI joint venture starting in 2027.

Q4-to-date volume is running up 17% year over year, which suggests the momentum carried into the new quarter.

Bears still have legitimate ammunition:

- Open interest growth stalled, with equity up 0.2%, rates up 1.2% and energy down 3.6% year over year at September 30, compared with roughly 8% OI growth at the time of the Q2 call.

- The 24/7 10-barrel WTI contract was withdrawn after a CFTC stay and commercial pushback.

- The October pricing changes add only about 0.5% to 1% to clearing fees, less than the usual annual increase.

- The Chicago cloud market migration is now targeted for late 2027.

- Perpetual-futures litigation with the CFTC remains unresolved, with a decision expected after December briefing.

Management did not change guidance, and the full-year expense outlook of about $1.695 billion was not revisited. Capital return eased to about $1 billion from $1.2 billion in Q2, with buybacks falling to $524 million from $695 million now that the Ostra proceeds are fully deployed.

The market setup is more complicated than the reacceleration implies. Shares rose 19.3% from the open after the July report to $295.31 heading into this release. That leaves them about 5.9% above the 200-day moving average and only 1.5% below the inter-earnings high of $299.92, which was set the day before the report. In other words, the stock rallied steadily off its post-Q2 low as volumes recovered, and much of the good news was likely anticipated. Investor sentiment remained slightly negative and was essentially unchanged, edging from -0.140 to -0.134. Investors have not grown more enthusiastic even as the price climbed. The Earnings Whispers trend readings lean positive on price, sequential growth and AVWAP, with momentum neutral. That is consistent with a stock that has been rewarded for improving activity but has not broken into euphoria.

The bottom line is that CME answered the question Q2 raised: record volumes, record market data and an active product pipeline put growth back into double digits, and early Q4 activity suggests it is not a one-quarter spike. But the quarter was a volume story rather than an earnings-leverage story. Pricing per contract is soft, license costs and lower interest income are eating into margins, open interest has flattened, and buybacks are slowing. With the stock entering the report near its quarterly high and sentiment still slightly negative, a penny-wide beat leaves little room for error. Sustained volume strength and traction from the new clearing and product launches will matter more than this quarter's surprise.